
Global launch forecast planning for an oncology asset
A large global pharmaceutical company wanted to better understand the product potential of a HER3 directed ADC for the treatment of patients with metastatic NSCLC
Viscadia was tasked with designing and building custom forecast platforms and processes catering to the U.S., EU5, Japan, and China to support cross-functional stakeholder objectives leading up to its launch